Risk factors for death in patients with β-thalassemia major: Results of a case-control study

Haematologica

Volumn 91, Issue 10, 2006, Pages 1420-1421

  Ceci, Adriana ^a   Baiardi, Paola ^a   Catapano, Mariana ^a   Felisi, Mariagrazia ^a   Cianciulli, Paolo ^b   De Sanctis, Vincenzo ^c   Del Vecchio, Giovanni Carlo ^d   Magnano, Carmelo ^e   Meo, Anna ^f   Maggio, Aurelio ^g  

^a Department of Biostatistics   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d POLICLINICO   (Italy)

^e GARIBALDI HOSPITAL   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

thalassemia; Deferiprone; Desferrioxamine; Iron overload

Indexed keywords

DEFERIPRONE; IRON CHELATING AGENT;

ADULT; ARTICLE; BETA THALASSEMIA; CASE CONTROL STUDY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; ITALY; MALE; MORTALITY; PATIENT COMPLIANCE; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33750019968     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
3. Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassaemic patients. Expert Opin Pharmacother 2003;4:1763-74.
4. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-6.
5. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-96.
6. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
7. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002;360:516-20.
8. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44.
9. Loukopoulos D. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1304-5.
10. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.